223 related articles for article (PubMed ID: 10667465)
1. Risk of breast cancer according to the status of HER-2/neu oncogene amplification.
Huang WY; Newman B; Millikan RC; Conway K; Hulka BS; Schell MJ; Liu ET
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):65-71. PubMed ID: 10667465
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.
Gammon MD; Hibshoosh H; Terry MB; Bose S; Schoenberg JB; Brinton LA; Bernstein JL; Thompson WD
Cancer Epidemiol Biomarkers Prev; 1999 May; 8(5):413-9. PubMed ID: 10350436
[TBL] [Abstract][Full Text] [Related]
3. The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease.
Supanaranond K; Sukarayodhin S; Tanyakaset M; Balachandra K; Jullaksorn D; Rienkijkarn M; Hoisanka N; Tantivanich S
Southeast Asian J Trop Med Public Health; 1997 Sep; 28(3):631-40. PubMed ID: 9561622
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis of HER-2/neu gene amplification in paraffin embedded tumour tissue in women with breast cancer.
Zadrozny M; Smolarz B; Romanowicz-Makowska H; Kozłowska E; Kulig A
Pol J Pathol; 2002; 53(4):189-93. PubMed ID: 12597335
[TBL] [Abstract][Full Text] [Related]
5. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women.
Nichols HB; Trentham-Dietz A; Love RR; Hampton JM; Hoang Anh PT; Allred DC; Mohsin SK; Newcomb PA
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):41-7. PubMed ID: 15668474
[TBL] [Abstract][Full Text] [Related]
6. Her-2/neu gene amplification in ductal carcinoma in situ of the breast.
Hoque A; Sneige N; Sahin AA; Menter DG; Bacus JW; Hortobagyi GN; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):587-90. PubMed ID: 12050101
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
8. Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers.
Anttinen J; Kuopio T; Nykanen M; Torkkeli H; Saari U; Juhola M
Anticancer Res; 2003; 23(5b):4213-8. PubMed ID: 14666627
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
10. Her-2/neu gene overexpression in breast carcinoma and its association with clinicopathological characteristics of the disease.
Ahmad A; Bano U; Gondal M; Khan A
J Coll Physicians Surg Pak; 2009 May; 19(5):297-9. PubMed ID: 19409162
[TBL] [Abstract][Full Text] [Related]
11. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
12. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
Grushko TA; Blackwood MA; Schumm PL; Hagos FG; Adeyanju MO; Feldman MD; Sanders MO; Weber BL; Olopade OI
Cancer Res; 2002 Mar; 62(5):1481-8. PubMed ID: 11888924
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu Ile655Val polymorphism and the risk of breast cancer.
Siddig A; Mohamed AO; Kamal H; Awad S; Hassan AH; Zilahi E; Al-Haj M; Bernsen R; Adem A
Ann N Y Acad Sci; 2008 Sep; 1138():84-94. PubMed ID: 18837888
[TBL] [Abstract][Full Text] [Related]
14. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
Homaei-Shandiz F; Ghavam-Nassiri MR; Sharifi N; Homaei-Shandiz AH; Taghizadeh-Kermani A; Torshizi SA; Ghafarzadegan K
Saudi Med J; 2006 Dec; 27(12):1810-4. PubMed ID: 17143354
[TBL] [Abstract][Full Text] [Related]
16. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.
Purnomosari D; Aryandono T; Setiaji K; Nugraha SB; Pals G; van Diest PJ
Biotech Histochem; 2006; 81(2-3):79-85. PubMed ID: 16908432
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
Tiwari RK; Borgen PI; Wong GY; Cordon-Cardo C; Osborne MP
Anticancer Res; 1992; 12(2):419-25. PubMed ID: 1349794
[TBL] [Abstract][Full Text] [Related]
20. Detection of HER-2/neu gene amplification in breast cancer using a novel polymerase chain reaction/ligase detection reaction technique.
Nathanson DR; Nash GM; Chen B; Gerald W; Paty PB
J Am Coll Surg; 2003 Sep; 197(3):419-25. PubMed ID: 12946797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
